论文部分内容阅读
目的 研究经导管肝动脉化疗栓塞 (TACE)联合B超引导下经细针门静脉化疗栓塞(PVE)治疗原发性肝癌的疗效。方法 原发性肝癌 2 0 9例 ,其中TACE 10 4例 ,TACE +PVE 10 5例。结果 TACE组和TACE +PVE组总有效率 (CR +PR)分别为 37.5 %和 5 7.2 % ,差异有显著性 (P <0 .0 1)。门静脉癌栓消失 +缩小率分别为 2 2 .2 %和 6 8.8% ,差异有显著性 (P <0 .0 1)。 1,2 ,3年生存率TACE组分别为 6 5 .1%、36 .3%和 2 0 .5 % ;TACE +PVE组分别为 95 .6 %、5 9.6 %和 39.1% ,两组差异有显著性 (P <0 .0 5 )。结论 经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌疗效优于单纯TACE。B超引导下经细针PVE操作简便 ,并发症少 ,值得临床推广使用。
Objective To study the effect of transcatheter arterial chemoembolization (TACE) combined with ultrasound-guided fine-needle portal vein chemoembolization (PVE) in the treatment of primary liver cancer. METHODS: A total of 209 patients with primary liver cancer were treated with TACE 104 and TACE + PVE 105. Results The total effective rates (CR + PR) of TACE group and TACE + PVE group were 37.5 % and 5 7.2 %, respectively, and the difference was significant (P < 0.01). The rate of disappearance and reduction of portal vein tumor emboli was 22.2% and 6.8%, respectively, with a significant difference (P < 0.01). The 1, 2 and 3 year survival rates in the TACE group were 65.1%, 36.3%, and 20.5%, respectively; the TACE + PVE group was 95.6%, 5.6%, and 39.1%, respectively. Significant (P < 0.05). Conclusion Transcatheter arterial chemoembolization and B-ultrasonography-guided dual-arterial chemoembolization with fine needle portal vein is superior to TACE alone in the treatment of primary hepatocellular carcinoma. Under the guidance of B-ultrasound, the fine-needle PVE is easy to operate and has few complications. It is worthy of clinical promotion.